Last reviewed · How we verify
Methylscopolamine (METHSCOPOLAMINE)
Methylscopolamine, also known as Methscopolamine, is a small molecule anticholinergic drug developed by Fougera Pharms and approved by the FDA in 1953. It targets the muscarinic acetylcholine receptor M3 and is used to treat various conditions such as allergic rhinitis, common cold, cough, irritable bowel syndrome, nasal congestion, and vasomotor rhinitis. The drug is off-patent and has multiple generic manufacturers. Key safety considerations include its potential to cause dry mouth, blurred vision, and constipation. As an anticholinergic, it works by blocking the action of acetylcholine, a neurotransmitter that stimulates muscle contraction and gland secretion.
At a glance
| Generic name | METHSCOPOLAMINE |
|---|---|
| Sponsor | Fougera Pharms |
| Drug class | Anticholinergic |
| Target | Muscarinic acetylcholine receptor M3 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
- Allergic rhinitis
- Common cold
- Cough
- Irritable bowel syndrome
- Nasal congestion
- Nasal discharge
- Vasomotor rhinitis
Common side effects
- Tachycardia
- Palpitation
- Anaphylaxis
- Headaches
- Nervousness
- Mental confusion
- Drowsiness
- Dizziness
- Blurred vision
- Dilation of the pupil
- Cycloplegia
- Increased ocular tension
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methylscopolamine CI brief — competitive landscape report
- Methylscopolamine updates RSS · CI watch RSS
- Fougera Pharms portfolio CI